Egnach, October 17, 2023 – The brain implant against tinnitus announced by the Neuralink company does not come now. Research is focused on the area of paralysis and now begins with the clinical study after receiving the permission of the US drug authority (FDA). Commercial use will then be available in 10 years at the earliest only for the area of paralysis.
Once again, the expectations of the tinnitus patients were disappointed. Last year, research on the medication OTO-313 of the American company Otonomy Inc. was hired according to the second clinical study because the placebo had a better effect in the patients. This means that tinniwell remains the only study -documented therapy against tinnitus worldwide.
++ About Resaphene Suisse AG
Resaphene Suisse AG, based in Egnach, Switzerland, is a medical technology company that was founded in 2015 and has been selling a tinnitus therapy device under the name tinniwell since 2016.
++ Contact for questions:
Resaphene Suisse AG
Mrs. Anke Rauterkus (Chief Executive Officer)
T. +41 714500668